This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
16 Oct 2018

Cambrex invests $3m to upgrade generic API manufacturing facilities at Milan site

The investment increases the overall capacity and capabilities of the facility, and its flexibility.

Cambrex is investing approximately $3 million to increase the capacity and efficiency of one of its cGMP manufacturing facilities at its site in Paullo, Milan, Italy. The investment will include the installation of a new 12,000-L reactor, as well as reconfiguration of the layout to allow for the replacement of existing centrifuges with new, more efficient equipment.

The 1,350 m2 (approx. 14,500 sq. ft) facility manufactures intermediates and APIs under GMP conditions, and this investment is part of a campaign by Cambrex of continuous improvement across its global network of manufacturing sites.

“This investment not only increases the overall capacity and capabilities of the facility, but also its flexibility, allowing us to work more efficiently,” commented Aldo Magnini, Managing Director, Cambrex Milan. “The generics portfolio is an important aspect of Cambrex’s business strategy and we have undertaken a number of improvements and expansions at the site to ensure we have the ability to meet the future demands of the industry.”

In June 2018, Cambrex announced an expansion to the R&D laboratories at Paullo, and in 2017 increased the site’s capabilities to handle and manufacture highly potent APIs.

Cambrex currently manufactures over 70 generic APIs which are produced to cGMP standards. The Milan site comprises seven production departments, supported by a pilot plant, kilo-scale plant and development and analytical laboratories.

Mentioned Companies
Cambrex
View company profile

Related News